Company intelligence / Profile preview
Canntab Therapeutics Limited
- Ownership
- Private
- Development stage
- Other
Overview
Developing pharmaceutical-grade oral solid dosage forms of cannabinoids including extended release, immediate release, and bi-layer tablets; seeking regulatory approvals in Canada and partnerships for commercialization; no advanced clinical trial data reported.
- Therapeutic areas
- RheumatologyPsychiatryNeurologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Canntab Therapeutics Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Canntab Therapeutics Limited.